Clinical findings and responses to biologic agents are increasing the evidence that undifferentiated spondyloarthritis (SpA) may represent the earliest stage of ankylosing spondylitis and psoriatic arthritis. New results also lend support to the hypothesis that the SpA spectrum represents one clinical condition, but hurdles in improving classification and diagnosis remain.
